Overview and Scope
Oral solid dosage contract manufacturing refers to outsourcing the production of oral solid dosage forms of pharmaceuticals to third-party manufacturers. This outsourcing strategy allows pharmaceutical companies to focus on their core activities, such as research, development, and marketing, while leveraging the expertise and capabilities of contract manufacturing organizations (CMO) to efficiently produce high-quality oral solid dosage pharmaceuticals.
Sizing and Forecast
The oral solid dosage contract manufacturing market size has grown strongly in recent years. It will grow from $36.70 billion in 2023 to $39.39 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to the growing global population, prevalence of chronic diseases, and rise in focus on research and development.
The oral solid dosage contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $52.94 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing outsourcing by pharmaceutical companies, advancements in drug delivery technology, and increasing drug development activities. Major trends in the forecast period include advancements in drug delivery technology, integration of 3D printing, and advancements in controlled-release technologies.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-contract-manufacturing-global-market-report
Segmentation & Regional Insights
The oral solid dosage contract manufacturing market covered in this report is segmented –
1) By Product Type: Tablets, Capsules, Powders, Granules, Other Product Types
2) By Service: Drug Product Development, Fill Finish Product Manufacturing, API Manufacturing, Packaging And Labelling, Other Applications
3) By Therapeutic Area: Oncology, Cardiovascular Diseases, Metabolic Disorders, Neurological Disorders, infectious Diseases, Gastrointestinal Diseases, Other Therapeutic Areas
4) By End User: Large Size Companies, Medium And Small Size Companies
Asia Pacific was the largest region in the oral solid dosage contract manufacturing market in 2023. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16137&type=smp
Major Driver Impacting Market Growth
The increase in demand for generic drugs is expected to propel the growth of the oral solid dosage contract manufacturing market going forward. Generic drugs are medications that are bioequivalent to brand-name drugs in dosage, strength, safety, performance, quality, and intended use. The rising demand for generic drugs is attributed to patent expirations, cost containment efforts, regulatory incentives, and expanding access to healthcare. Oral solid dosage contract manufacturing significantly aids the production and distribution of generic drugs by leveraging the capabilities of contract manufacturers to enhance their operational efficiency, reduce costs, ensure high-quality production, and bring their products to market more swiftly and effectively. For instance, in 2022, according to the Food and Drug Administration, a US-based federal agency, it is estimated that 91% of all prescriptions in the USA were filled with generic drugs, with more than 32,000 generic drugs approved by the FDA (Food and Drug Administration). Therefore, the demand for generic drugs drives the growth of the oral solid dosage contract manufacturing market.
Key Industry Players
Major companies operating in the oral solid dosage contract manufacturing market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Siemens Healthineers AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under the CordenPharma brand, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation
The oral solid dosage contract manufacturing market report table of contents includes:
1. Executive Summary
2. Oral Solid Dosage Contract Manufacturing Market Characteristics
3. Oral Solid Dosage Contract Manufacturing Market Trends And Strategies
4. Oral Solid Dosage Contract Manufacturing Market – Macro Economic Scenario
5. Global Oral Solid Dosage Contract Manufacturing Market Size and Growth
.
.
.
32. Global Oral Solid Dosage Contract Manufacturing Market Competitive Benchmarking
33. Global Oral Solid Dosage Contract Manufacturing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Oral Solid Dosage Contract Manufacturing Market
35. Oral Solid Dosage Contract Manufacturing Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
